Skip to main content
SpringerLink
Log in

Pharmacokinetics of a new anticancer drug, navelbine, in patients

Comparative study of radioimmunologic and radioactive determination methods

  • Original Articles
  • Vinca Alkaloid, Navelbine, Pharmacokinetics
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

A study was designed to investigate the fate of navelbine (NVB) and its excretion routes in two cancer patients treated with tritiated NVB (30mg/m2) by i.v. bolus injection. Plasma and red blood cell concentrations and urine and stool elimination were monitored over long periods of time. NVB plasma and urine concentrations were measured by both radioimmunoassay (RIA) and direct radioactive (RA) determination. Samples were also analyzed by high-performance liquid chromatography to evaluate the importance of NVB metabolism. Whereas the major excretion route for NVB was the stool (from 34% to 58.4% of the total dose given over 21 days), urinary excretion was low (about 21% within the same time period), corresponding mainly to that of unchanged drug. Thus, a good correlation was found between RIA and RA determinations in urine. In contrast, plasma area under the curve (AUC) values obtained after RA and RIA analysis differed markedly (AUC RIA/AUC RA=0.23–0.31), demonstrating that a significant proportion of the plasma-circulating drug was biotransformed, mainly during the last elimination phase. This could have important pharmacologic and toxicologic implications in clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bender RA, Castle MC, Margileth DA, Oliverio VT (1977) The pharmacokinetics of (3H)-vincristine in man. Clin Pharmacol Ther 22:430–438

    Google Scholar 

  2. Cano JP, Rahmani R, Favre R, Barbet J, Carcassonne Y (1985) In vivo and in vitro pharmacokinetic studies on antitumor vinca alkaloids. In: Ishigami J (ed) Recent advances in chemotherapy. Anticancer section. University of Tokyo Press, Tokyo, pp 118–120

    Google Scholar 

  3. Cano JP, Boré P, Henry JC, Placidi M, Rahmani R (1986) Elimination and metabolic studies on two semi-synthetic vinca alkaloids (V.A.), navelbine (NVB) and vindesine (VDS), in rats. Abstract 10.12, fifth NCI-EORTC Symposium on New Drugs in Cancer Therapy. Amsterdam

  4. Favre R, Garnier G, Depierre A, Samak R, Cano JP, Carcassonne Y (1985) A phase I study of navelbine. In: Ishigami J (ed) Recent advances in chemotherapy Anticancer section. University of Tokyo Press, Tokyo pp 641–642

    Google Scholar 

  5. Gibaldi M, Perrier D (1982) Pharmacokinetics. In: Swarbrick J (ed) Drugs and the pharmaceutical sciences, vol 15. Marcel Dekker, New York

    Google Scholar 

  6. Maral R, Bourut C, Chenu E, Mathé G (1984) Experimental antitumor activity of 5′-noranhydrovinblastine: navelbine. Cancer Lett 22:49–54

    Google Scholar 

  7. Nelson RL, Dike RW, Root MA (1979) Clinical pharmacokinetics of vindesine. Cancer Chemother Pharmacol 2: 243–246

    Google Scholar 

  8. Owellen RJ, Hartke CA (1975) The pharmacokinetics of 4-acetyl tritium vinblastine in two patients. Cancer Res 35: 975–980

    Google Scholar 

  9. Owellen RJ, Hartke CA, Hains FO (1977) The pharmacokinetics and metabolism of vinblastine in humans. Cancer Res 37: 2597–2602

    Google Scholar 

  10. Potier P, Guénard D, Zavala F (1979) Résultats récents dans le domaine des alcaloïdes antitumoraux du groupe de la Vinblastine. Etudes biologiques. CR Soc Biol 173:414–424

    Google Scholar 

  11. Rahmani R, Barbet J, Cano JP (1983) A 125I-radiolabelled probe for vinblastine and vindesine radioimmunoassays: applications to measurements of vindesine plasma levels in man after intravenous injections and long term infusions. Clin Chim Acta 129:57–69

    Google Scholar 

  12. Rahmani R, Martin M, Barbet J, Cano JP (1984) Radioimmunoassay and preliminary pharmacokinetic studies in rats of 5′-noranhydrovinblastine (Navelbine). Cancer Res 44: 5609–5613

    Google Scholar 

  13. Rahmani R, Martin M, Favre R, Cano JP, Barbet J (1984) Clinical pharmacokinetics of vindesine: repeated treatments by intravenous bolus injection. Eur J Cancer Clin Oncol 20: 1409–1417

    Google Scholar 

  14. Rahmani R, Guéritte F, Martin M, Just S, Cano JP, Barbet J (1986) Comparative pharmacokinetics of antitumor vinca alkaloids: intravenous bolus injection of navelbine and related alkaloïds to cancer patients and rats. Cancer Chemother Pharmacol 16:223–228

    Google Scholar 

  15. Rahmani R, Bruno R, Iliadis A, Favre R, Just S, Barbet J, Cano JP (1987) Clinical pharmacokinetics of the antitumor drug navelbine (5′-noranhydrovinblastine). Cancer Res 47: 5796–5799

    Google Scholar 

  16. Ribaud P, Gouveia J, Maral R, Potier P, Jasmin C, Mathé G (1981) Phase I study of 5′-noranhydrovinblastine (navelbine, NVB). Proc Am Assoc Cancer Res 22:368

    Google Scholar 

  17. Roussakis C, Dabouis G, Gratas C, Andouin A, Viaud P, Le Mével B, Harousseau JL (1986) Establishment in culture of a bronchial epidermoid carcinoma cell line of human origin. Abstract 4.12, fifth NCI-EORTC Symposium on New Drugs in Cancer Therapy. Amsterdam

  18. Takoudju M, Cros S, Lataste H, Samak R, Weight M (1985) Comparative in vitro and in vivo study of navelbine ditartrate with the two antitumor compounds vinblastine and vincristine. In: Ishigami J (ed) Recent advances in chemotherapy. Anticancer section. University of Tokyo Press, Tokyo, pp 528–529

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratoire de Pharmacocinétique, INSERM U 278, 27 Bd Jean Moulin, F-13385, Marseille, Cedex 5, France

    P. Boré, R. Rahmani & J. P. Cano

  2. Institut de Pathologie, Université de Liège, Bât. B 23, B-4000, Sart-Tilman par Liège, Belgique

    J. van Cantfort

  3. Clinique Sainte Elisabeth, Montagne Sainte Walburge, B-4000, Liège, Bélgique

    C. Focan

Authors
  1. P. Boré
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Rahmani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. van Cantfort
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Focan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. P. Cano
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Boré, P., Rahmani, R., van Cantfort, J. et al. Pharmacokinetics of a new anticancer drug, navelbine, in patients. Cancer Chemother. Pharmacol. 23, 247–251 (1989). https://doi.org/10.1007/BF00451650

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00451650

Keywords

Search

Navigation